LSB

LakeShore Biopharma
LSB
Market cap $63.9M

3.35 USD

-0.35

9.46%

At close Oct 17, 4:00 PM EDT

1 day

-9.46%

5 days

-10.19%

1 month

-95.77%

3 months

-93.02%

6 months

-96.42%

Year to date

-93.43%

1 year

-95.08%

5 years

-99.67%

About: LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.

Employees: 758

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

257% more capital invested

Capital invested by funds: $3.79M [Q1] → $13.5M (+$9.75M) [Q2]

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

22% more funds holding

Funds holding: 9 [Q1] → 11 (+2) [Q2]

0.13% less ownership

Funds ownership: 2.85% [Q1] → 2.72% (-0.13%) [Q2]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for LSB.

See Analyst Rankings

Financial journalist opinion

LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance

GAITHERSBURG, Md. , Oct. 8, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it is providing financial guidance for the half year of its fiscal year of 2025 and reaffirming its financial guidance for the full year of its fiscal year 2025 ending on March 31, 2025 ("Fiscal Year 2025"), underlining the Company's strong execution and positive business momentum.

LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance

LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation

GAITHERSBURG, Md. , Sept. 27, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the results of its extraordinary general meeting (the "EGM") held on September 27, 2024 (Beijing Time) virtually via a Zoom video conference call.

LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation

Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024

GAITHERSBURG, Md. , Sept. 10, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it will hold an extraordinary general meeting of shareholders (the "EGM") at 10:00 a.m.

Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024

LakeShore Biopharma Announces Leadership Transitions

GAITHERSBURG, Md. , Sept. 4, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd.

LakeShore Biopharma Announces Leadership Transitions

LakeShore Biopharma Announces Financial Results for Fiscal Year 2024

Gross margin increased to 79.5%; product pipeline continues to advance Company anticipates double-digit year-over-year revenue growth and bottom line breakeven for Fiscal Year 2025 GAITHERSBURG, Md. , Aug. 15, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd.

LakeShore Biopharma Announces Financial Results for Fiscal Year 2024

LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition

GAITHERSBURG, Md. , July 5, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the Company received a shareholders' requisition dated June 14, 2024, issued by certain shareholders of the Company holding shares which carry in aggregate not less than 10% of all votes attaching to all issued and outstanding shares of the Company, including Yi Zhang, All Brilliance Investments Limited, Apex Pride Global Limited, Hopeful World Company Limited, and Acton Town International Limited (together, the "Requisitioning Shareholders"), requesting the directors of the Company to convene an extraordinary general meeting (the "EGM") of the Company (the "Requisition") to provide explanations to the shareholders of the Company on matters as described below: The circumstances leading to the filing of the United States Securities and Exchange Commission Form 6-K Report, filed on June 10, 2024 (the "SEC Report"), including the reasons for the resignation of each of the former directors specified in the SEC Report.

LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition

See News Rankings

Charts implemented using Lightweight Charts™